CRISPR Therapeutics AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRSP research report →
Range $52 – $110
Price Chart
About the company
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions.
- CEO
- Samarth Kulkarni
- IPO
- 2016
- Employees
- 393
- HQ
- Zug, ZG, CH
Get TickerSpark's AI analysis on CRSP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.79B
- P/E
- -8.48
- Fwd P/E
- 10.65
- PEG
- -1.04
- P/S
- 154.87
- P/B
- 2.36
- EV/EBITDA
- -9.76
- Div Yield
- 0.00%
- Gross Margin
- -676.53%
- Op Margin
- -2104.93%
- Net Margin
- -1812.07%
- ROE
- -25.59%
- ROIC
- -21.77%
Latest fiscal year · YoY change
- Revenue
- $3.51M-90.0%
- Gross Profit
- $-229,449,000-204.9%
- Op Income
- $-568,318,000
- Net Income
- $-581,599,000-58.8%
- EPS
- $-6.47-49.1%
- OCF Growth
- -141.7%
- FCF Growth
- -139.1%
- 52W High
- $63.45
- 52W Low
- $38.18
- 50D MA
- $50.96
- 200D MA
- $52.31
- Beta
- 1.90
- RSI (14)
- 28
- Avg Volume
- 1.73M
No earnings-call transcripts are available for CRSP yet.
- Free Float
- 99.5%
- Shares Outstanding
- 97.00M
- Float Shares
- 96.49M
of shares held by institutions
560 13F filers
Buy/sell ratio 1.60. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CRSP, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Thomas SuozziHouse · NY03 | Sell | Sep 20, 21 | Filing → |
| Thomas SuozziHouse · NY03 | Buy | Jun 3, 21 | Filing → |
| Marjorie Taylor GreeneHouse · GA14 | Buy | Jan 21, 21 | Filing → |
| James Mountain InhofeSenate · OK | Sell | Jan 5, 21 | Filing → |
| James Mountain InhofeSenate · OK | Sell | Dec 22, 20 | Filing → |
| James Mountain InhofeSenate · OK | Sell | Jun 19, 18 | Filing → |
| James Mountain InhofeSenate · OK | Buy | Oct 19, 17 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ark Investment Management LLC | 10.06M | ▲ 595.90K |
| Blackrock, Inc. | 8.30M | ▼ 49.10K |
| State Street Corp | 4.99M | ▲ 672.38K |
| Capital World Investors | 4.74M | ▼ 10.39K |
| Orbis Allan Gray Ltd | 4.52M | ▼ 929.90K |
| Gsk PLC | 2.61M | ▼ 612.21K |
| Geode Capital Management, LLC | 2.51M | ▲ 2.29K |
| Vanguard Group Inc | 2.27M | ▼ 96.25K |
| Sr One Capital Management, LP | 2.04M | 0 |
| Two Sigma Investments, LP | 2.02M | ▲ 27.42K |
| Fmr LLC | 1.90M | ▼ 11.76K |
| Bank Of America Corp | 1.74M | ▲ 584.21K |
Held by 380 ETFs
Biggest fund positions in CRSP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Kulkarni Samarth | other | 100,000 |
| Nov 4, 26 | Sakhamuri Sivakesava | other | 90,000 |
| Nov 4, 26 | Sakhamuri Sivakesava | other | 40,000 |
| Nov 2, 26 | Sakhamuri Sivakesava | other | 0 |
| Oct 26, 26 | Silver Andrew Jacob | other | 18,000 |
| Oct 26, 26 | Silver Andrew Jacob | other | 9,000 |
| Oct 26, 26 | KASINGER JAMES R. | other | 18,000 |
| Oct 26, 26 | KASINGER JAMES R. | other | 9,000 |
| Oct 26, 26 | Kulkarni Samarth | other | 57,500 |
| Oct 26, 26 | Kulkarni Samarth | other | 28,750 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CRSP coverage
Recent articles, reports, and earnings notes.

Gene Therapy Stocks That Turn Science Into Sales: 7 Picks
A countdown of seven gene therapy stocks spans commercial treatments, gene-editing platforms, rare-disease specialists, and diversified pharmaceutical exposure.

Biotech’s breakout is a catalyst trade, not a new market leader
Biotech’s sharp outperformance is real, but the rally is rewarding profitable franchises and identifiable catalysts rather than lifting the entire sector. The better opportunity is selective exposure to de-risked pipelines, not indiscriminate bets on biotech as technology’s replacement.

The rate-cut trade is splitting in two: buy biotech, not every growth stock
A softer July PCE report could revive duration, but the best rebound candidates are profitable, catalyst-backed biotechs rather than every cash-burning growth stock. If inflation keeps yields high, JPM and Goldman offer the more defensible earnings-supported trade.
Want a deeper read on CRSP?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
zacks.com · Nov 17
CRISPR Therapeutics Eyes Late-Stage Trials as Key Data and CASGEVY Demand Build
marketbeat.com · Nov 17
Crispr Therapeutics: The Recent 40% Drop In Short Interest Indicates Deteriorating Bearish Sentiment
seekingalpha.com · Nov 10
CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
globenewswire.com · Nov 10
CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026
globenewswire.com · Nov 9
CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases
globenewswire.com · Nov 8
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
zacks.com · Nov 6
CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition
globenewswire.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.